- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Recombinant Vector Vaccines market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Recombinant Vector Vaccines market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. For Adult accounting for % of the Recombinant Vector Vaccines global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Varicella segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., Novartis, GSK, CNBG, and ChengDa Bio, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Recombinant Vector Vaccines market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, tetanus
Pneumococcal
Others
Market segment by Application can be divided into
For Adult
For Child
The key market players for global Recombinant Vector Vaccines market are listed below:
SANOFI PASTEUR S.A.
Novartis
GSK
CNBG
ChengDa Bio
Changsheng Life
Zhifei
SINOVAC BIOTECH
NuoCheng Bio
Hualan Bio
Kangtai
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Vector Vaccines product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Recombinant Vector Vaccines, with price, sales, revenue and global market share of Recombinant Vector Vaccines from 2019 to 2022.
Chapter 3, the Recombinant Vector Vaccines competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Vector Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Recombinant Vector Vaccines market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Vector Vaccines.
Chapter 13, 14, and 15, to describe Recombinant Vector Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Recombinant Vector Vaccines Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Recombinant Vector Vaccines Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Varicella
1.2.3 Influenza
1.2.4 Polio
1.2.5 Hepatitis A
1.2.6 Rabies
1.2.7 BCG
1.2.8 Hepatitis B
1.2.9 Pertussis, Diphtheria, tetanus
1.2.10 Pneumococcal
1.2.11 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Recombinant Vector Vaccines Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 For Adult
1.3.3 For Child
1.4 Global Recombinant Vector Vaccines Market Size & Forecast
1.4.1 Global Recombinant Vector Vaccines Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Recombinant Vector Vaccines Sales in Volume (2017-2028)
1.4.3 Global Recombinant Vector Vaccines Price (2017-2028)
1.5 Global Recombinant Vector Vaccines Production Capacity Analysis
1.5.1 Global Recombinant Vector Vaccines Total Production Capacity (2017-2028)
1.5.2 Global Recombinant Vector Vaccines Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Recombinant Vector Vaccines Market Drivers
1.6.2 Recombinant Vector Vaccines Market Restraints
1.6.3 Recombinant Vector Vaccines Trends Analysis
2 Manufacturers Profiles
2.1 SANOFI PASTEUR S.A.
2.1.1 SANOFI PASTEUR S.A. Details
2.1.2 SANOFI PASTEUR S.A. Major Business
2.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product and Services
2.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Recombinant Vector Vaccines Product and Services
2.2.4 Novartis Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Recombinant Vector Vaccines Product and Services
2.3.4 GSK Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 CNBG
2.4.1 CNBG Details
2.4.2 CNBG Major Business
2.4.3 CNBG Recombinant Vector Vaccines Product and Services
2.4.4 CNBG Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 ChengDa Bio
2.5.1 ChengDa Bio Details
2.5.2 ChengDa Bio Major Business
2.5.3 ChengDa Bio Recombinant Vector Vaccines Product and Services
2.5.4 ChengDa Bio Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Changsheng Life
2.6.1 Changsheng Life Details
2.6.2 Changsheng Life Major Business
2.6.3 Changsheng Life Recombinant Vector Vaccines Product and Services
2.6.4 Changsheng Life Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Zhifei
2.7.1 Zhifei Details
2.7.2 Zhifei Major Business
2.7.3 Zhifei Recombinant Vector Vaccines Product and Services
2.7.4 Zhifei Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 SINOVAC BIOTECH
2.8.1 SINOVAC BIOTECH Details
2.8.2 SINOVAC BIOTECH Major Business
2.8.3 SINOVAC BIOTECH Recombinant Vector Vaccines Product and Services
2.8.4 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 NuoCheng Bio
2.9.1 NuoCheng Bio Details
2.9.2 NuoCheng Bio Major Business
2.9.3 NuoCheng Bio Recombinant Vector Vaccines Product and Services
2.9.4 NuoCheng Bio Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Hualan Bio
2.10.1 Hualan Bio Details
2.10.2 Hualan Bio Major Business
2.10.3 Hualan Bio Recombinant Vector Vaccines Product and Services
2.10.4 Hualan Bio Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Kangtai
2.11.1 Kangtai Details
2.11.2 Kangtai Major Business
2.11.3 Kangtai Recombinant Vector Vaccines Product and Services
2.11.4 Kangtai Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Recombinant Vector Vaccines Breakdown Data by Manufacturer
3.1 Global Recombinant Vector Vaccines Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Recombinant Vector Vaccines Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Recombinant Vector Vaccines
3.4 Market Concentration Rate
3.4.1 Top 3 Recombinant Vector Vaccines Manufacturer Market Share in 2021
3.4.2 Top 6 Recombinant Vector Vaccines Manufacturer Market Share in 2021
3.5 Global Recombinant Vector Vaccines Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Recombinant Vector Vaccines Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Recombinant Vector Vaccines Market Size by Region
4.1.1 Global Recombinant Vector Vaccines Sales in Volume by Region (2017-2028)
4.1.2 Global Recombinant Vector Vaccines Revenue by Region (2017-2028)
4.2 North America Recombinant Vector Vaccines Revenue (2017-2028)
4.3 Europe Recombinant Vector Vaccines Revenue (2017-2028)
4.4 Asia-Pacific Recombinant Vector Vaccines Revenue (2017-2028)
4.5 South America Recombinant Vector Vaccines Revenue (2017-2028)
4.6 Middle East and Africa Recombinant Vector Vaccines Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Recombinant Vector Vaccines Sales in Volume by Type (2017-2028)
5.2 Global Recombinant Vector Vaccines Revenue by Type (2017-2028)
5.3 Global Recombinant Vector Vaccines Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Recombinant Vector Vaccines Sales in Volume by Application (2017-2028)
6.2 Global Recombinant Vector Vaccines Revenue by Application (2017-2028)
6.3 Global Recombinant Vector Vaccines Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Recombinant Vector Vaccines Sales by Type (2017-2028)
7.2 North America Recombinant Vector Vaccines Sales by Application (2017-2028)
7.3 North America Recombinant Vector Vaccines Market Size by Country
7.3.1 North America Recombinant Vector Vaccines Sales in Volume by Country (2017-2028)
7.3.2 North America Recombinant Vector Vaccines Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Recombinant Vector Vaccines Sales by Type (2017-2028)
8.2 Europe Recombinant Vector Vaccines Sales by Application (2017-2028)
8.3 Europe Recombinant Vector Vaccines Market Size by Country
8.3.1 Europe Recombinant Vector Vaccines Sales in Volume by Country (2017-2028)
8.3.2 Europe Recombinant Vector Vaccines Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Recombinant Vector Vaccines Sales by Type (2017-2028)
9.2 Asia-Pacific Recombinant Vector Vaccines Sales by Application (2017-2028)
9.3 Asia-Pacific Recombinant Vector Vaccines Market Size by Region
9.3.1 Asia-Pacific Recombinant Vector Vaccines Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Recombinant Vector Vaccines Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Recombinant Vector Vaccines Sales by Type (2017-2028)
10.2 South America Recombinant Vector Vaccines Sales by Application (2017-2028)
10.3 South America Recombinant Vector Vaccines Market Size by Country
10.3.1 South America Recombinant Vector Vaccines Sales in Volume by Country (2017-2028)
10.3.2 South America Recombinant Vector Vaccines Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Recombinant Vector Vaccines Sales by Type (2017-2028)
11.2 Middle East & Africa Recombinant Vector Vaccines Sales by Application (2017-2028)
11.3 Middle East & Africa Recombinant Vector Vaccines Market Size by Country
11.3.1 Middle East & Africa Recombinant Vector Vaccines Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Recombinant Vector Vaccines Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Recombinant Vector Vaccines and Key Manufacturers
12.2 Manufacturing Costs Percentage of Recombinant Vector Vaccines
12.3 Recombinant Vector Vaccines Production Process
12.4 Recombinant Vector Vaccines Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Recombinant Vector Vaccines Typical Distributors
13.3 Recombinant Vector Vaccines Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Recombinant Vector Vaccines Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Recombinant Vector Vaccines Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. SANOFI PASTEUR S.A. Basic Information, Manufacturing Base and Competitors
Table 4. SANOFI PASTEUR S.A. Major Business
Table 5. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product and Services
Table 6. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Novartis Basic Information, Manufacturing Base and Competitors
Table 8. Novartis Major Business
Table 9. Novartis Recombinant Vector Vaccines Product and Services
Table 10. Novartis Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. GSK Basic Information, Manufacturing Base and Competitors
Table 12. GSK Major Business
Table 13. GSK Recombinant Vector Vaccines Product and Services
Table 14. GSK Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. CNBG Basic Information, Manufacturing Base and Competitors
Table 16. CNBG Major Business
Table 17. CNBG Recombinant Vector Vaccines Product and Services
Table 18. CNBG Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. ChengDa Bio Basic Information, Manufacturing Base and Competitors
Table 20. ChengDa Bio Major Business
Table 21. ChengDa Bio Recombinant Vector Vaccines Product and Services
Table 22. ChengDa Bio Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Changsheng Life Basic Information, Manufacturing Base and Competitors
Table 24. Changsheng Life Major Business
Table 25. Changsheng Life Recombinant Vector Vaccines Product and Services
Table 26. Changsheng Life Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Zhifei Basic Information, Manufacturing Base and Competitors
Table 28. Zhifei Major Business
Table 29. Zhifei Recombinant Vector Vaccines Product and Services
Table 30. Zhifei Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. SINOVAC BIOTECH Basic Information, Manufacturing Base and Competitors
Table 32. SINOVAC BIOTECH Major Business
Table 33. SINOVAC BIOTECH Recombinant Vector Vaccines Product and Services
Table 34. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. NuoCheng Bio Basic Information, Manufacturing Base and Competitors
Table 36. NuoCheng Bio Major Business
Table 37. NuoCheng Bio Recombinant Vector Vaccines Product and Services
Table 38. NuoCheng Bio Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 40. Hualan Bio Major Business
Table 41. Hualan Bio Recombinant Vector Vaccines Product and Services
Table 42. Hualan Bio Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Kangtai Basic Information, Manufacturing Base and Competitors
Table 44. Kangtai Major Business
Table 45. Kangtai Recombinant Vector Vaccines Product and Services
Table 46. Kangtai Recombinant Vector Vaccines Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Global Recombinant Vector Vaccines Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Doses)
Table 48. Global Recombinant Vector Vaccines Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 49. Market Position of Manufacturers in Recombinant Vector Vaccines, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 50. Global Recombinant Vector Vaccines Production Capacity by Company, (K Doses): 2020 VS 2021
Table 51. Head Office and Recombinant Vector Vaccines Production Site of Key Manufacturer
Table 52. Recombinant Vector Vaccines New Entrant and Capacity Expansion Plans
Table 53. Recombinant Vector Vaccines Mergers & Acquisitions in the Past Five Years
Table 54. Global Recombinant Vector Vaccines Sales by Region (2017-2022) & (K Doses)
Table 55. Global Recombinant Vector Vaccines Sales by Region (2023-2028) & (K Doses)
Table 56. Global Recombinant Vector Vaccines Revenue by Region (2017-2022) & (USD Million)
Table 57. Global Recombinant Vector Vaccines Revenue by Region (2023-2028) & (USD Million)
Table 58. Global Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 59. Global Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 60. Global Recombinant Vector Vaccines Revenue by Type (2017-2022) & (USD Million)
Table 61. Global Recombinant Vector Vaccines Revenue by Type (2023-2028) & (USD Million)
Table 62. Global Recombinant Vector Vaccines Price by Type (2017-2022) & (USD/Dose)
Table 63. Global Recombinant Vector Vaccines Price by Type (2023-2028) & (USD/Dose)
Table 64. Global Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 65. Global Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 66. Global Recombinant Vector Vaccines Revenue by Application (2017-2022) & (USD Million)
Table 67. Global Recombinant Vector Vaccines Revenue by Application (2023-2028) & (USD Million)
Table 68. Global Recombinant Vector Vaccines Price by Application (2017-2022) & (USD/Dose)
Table 69. Global Recombinant Vector Vaccines Price by Application (2023-2028) & (USD/Dose)
Table 70. North America Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 71. North America Recombinant Vector Vaccines Sales by Country (2023-2028) & (K Doses)
Table 72. North America Recombinant Vector Vaccines Revenue by Country (2017-2022) & (USD Million)
Table 73. North America Recombinant Vector Vaccines Revenue by Country (2023-2028) & (USD Million)
Table 74. North America Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 75. North America Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 76. North America Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 77. North America Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 78. Europe Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 79. Europe Recombinant Vector Vaccines Sales by Country (2023-2028) & (K Doses)
Table 80. Europe Recombinant Vector Vaccines Revenue by Country (2017-2022) & (USD Million)
Table 81. Europe Recombinant Vector Vaccines Revenue by Country (2023-2028) & (USD Million)
Table 82. Europe Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 83. Europe Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 84. Europe Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 85. Europe Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 86. Asia-Pacific Recombinant Vector Vaccines Sales by Region (2017-2022) & (K Doses)
Table 87. Asia-Pacific Recombinant Vector Vaccines Sales by Region (2023-2028) & (K Doses)
Table 88. Asia-Pacific Recombinant Vector Vaccines Revenue by Region (2017-2022) & (USD Million)
Table 89. Asia-Pacific Recombinant Vector Vaccines Revenue by Region (2023-2028) & (USD Million)
Table 90. Asia-Pacific Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 91. Asia-Pacific Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 92. Asia-Pacific Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 93. Asia-Pacific Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 94. South America Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 95. South America Recombinant Vector Vaccines Sales by Country (2023-2028) & (K Doses)
Table 96. South America Recombinant Vector Vaccines Revenue by Country (2017-2022) & (USD Million)
Table 97. South America Recombinant Vector Vaccines Revenue by Country (2023-2028) & (USD Million)
Table 98. South America Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 99. South America Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 100. South America Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 101. South America Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 102. Middle East & Africa Recombinant Vector Vaccines Sales by Region (2017-2022) & (K Doses)
Table 103. Middle East & Africa Recombinant Vector Vaccines Sales by Region (2023-2028) & (K Doses)
Table 104. Middle East & Africa Recombinant Vector Vaccines Revenue by Region (2017-2022) & (USD Million)
Table 105. Middle East & Africa Recombinant Vector Vaccines Revenue by Region (2023-2028) & (USD Million)
Table 106. Middle East & Africa Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 107. Middle East & Africa Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 108. Middle East & Africa Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 109. Middle East & Africa Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 110. Recombinant Vector Vaccines Raw Material
Table 111. Key Manufacturers of Recombinant Vector Vaccines Raw Materials
Table 112. Direct Channel Pros & Cons
Table 113. Indirect Channel Pros & Cons
Table 114. Recombinant Vector Vaccines Typical Distributors
Table 115. Recombinant Vector Vaccines Typical Customers
List of Figures
Figure 1. Recombinant Vector Vaccines Picture
Figure 2. Global Recombinant Vector Vaccines Revenue Market Share by Type in 2021
Figure 3. Varicella
Figure 4. Influenza
Figure 5. Polio
Figure 6. Hepatitis A
Figure 7. Rabies
Figure 8. BCG
Figure 9. Hepatitis B
Figure 10. Pertussis, Diphtheria, tetanus
Figure 11. Pneumococcal
Figure 12. Others
Figure 13. Global Recombinant Vector Vaccines Revenue Market Share by Application in 2021
Figure 14. For Adult
Figure 15. For Child
Figure 16. Global Recombinant Vector Vaccines Revenue, (USD Million) & (K Doses): 2017 & 2021 & 2028
Figure 17. Global Recombinant Vector Vaccines Revenue and Forecast (2017-2028) & (USD Million)
Figure 18. Global Recombinant Vector Vaccines Sales (2017-2028) & (K Doses)
Figure 19. Global Recombinant Vector Vaccines Price (2017-2028) & (USD/Dose)
Figure 20. Global Recombinant Vector Vaccines Production Capacity (2017-2028) & (K Doses)
Figure 21. Global Recombinant Vector Vaccines Production Capacity by Geographic Region: 2022 VS 2028
Figure 22. Recombinant Vector Vaccines Market Drivers
Figure 23. Recombinant Vector Vaccines Market Restraints
Figure 24. Recombinant Vector Vaccines Market Trends
Figure 25. Global Recombinant Vector Vaccines Sales Market Share by Manufacturer in 2021
Figure 26. Global Recombinant Vector Vaccines Revenue Market Share by Manufacturer in 2021
Figure 27. Recombinant Vector Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 28. Top 3 Recombinant Vector Vaccines Manufacturer (Revenue) Market Share in 2021
Figure 29. Top 6 Recombinant Vector Vaccines Manufacturer (Revenue) Market Share in 2021
Figure 30. Global Recombinant Vector Vaccines Sales Market Share by Region (2017-2028)
Figure 31. Global Recombinant Vector Vaccines Revenue Market Share by Region (2017-2028)
Figure 32. North America Recombinant Vector Vaccines Revenue (2017-2028) & (USD Million)
Figure 33. Europe Recombinant Vector Vaccines Revenue (2017-2028) & (USD Million)
Figure 34. Asia-Pacific Recombinant Vector Vaccines Revenue (2017-2028) & (USD Million)
Figure 35. South America Recombinant Vector Vaccines Revenue (2017-2028) & (USD Million)
Figure 36. Middle East & Africa Recombinant Vector Vaccines Revenue (2017-2028) & (USD Million)
Figure 37. Global Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 38. Global Recombinant Vector Vaccines Revenue Market Share by Type (2017-2028)
Figure 39. Global Recombinant Vector Vaccines Price by Type (2017-2028) & (USD/Dose)
Figure 40. Global Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 41. Global Recombinant Vector Vaccines Revenue Market Share by Application (2017-2028)
Figure 42. Global Recombinant Vector Vaccines Price by Application (2017-2028) & (USD/Dose)
Figure 43. North America Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 44. North America Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 45. North America Recombinant Vector Vaccines Sales Market Share by Country (2017-2028)
Figure 46. North America Recombinant Vector Vaccines Revenue Market Share by Country (2017-2028)
Figure 47. United States Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Canada Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Mexico Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Europe Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 51. Europe Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 52. Europe Recombinant Vector Vaccines Sales Market Share by Country (2017-2028)
Figure 53. Europe Recombinant Vector Vaccines Revenue Market Share by Country (2017-2028)
Figure 54. Germany Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. France Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. United Kingdom Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Russia Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Italy Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Asia-Pacific Recombinant Vector Vaccines Sales Market Share by Region (2017-2028)
Figure 60. Asia-Pacific Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 61. Asia-Pacific Recombinant Vector Vaccines Sales Market Share by Region (2017-2028)
Figure 62. Asia-Pacific Recombinant Vector Vaccines Revenue Market Share by Region (2017-2028)
Figure 63. China Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Japan Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Korea Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. India Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Southeast Asia Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Australia Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. South America Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 70. South America Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 71. South America Recombinant Vector Vaccines Sales Market Share by Country (2017-2028)
Figure 72. South America Recombinant Vector Vaccines Revenue Market Share by Country (2017-2028)
Figure 73. Brazil Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Argentina Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Middle East & Africa Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 76. Middle East & Africa Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 77. Middle East & Africa Recombinant Vector Vaccines Sales Market Share by Region (2017-2028)
Figure 78. Middle East & Africa Recombinant Vector Vaccines Revenue Market Share by Region (2017-2028)
Figure 79. Turkey Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Egypt Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Saudi Arabia Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. South Africa Recombinant Vector Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. Manufacturing Cost Structure Analysis of Recombinant Vector Vaccines in 2021
Figure 84. Manufacturing Process Analysis of Recombinant Vector Vaccines
Figure 85. Recombinant Vector Vaccines Industrial Chain
Figure 86. Sales Channel: Direct Channel vs Indirect Channel
Figure 87. Methodology
Figure 88. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
